Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer

CONCLUSION: Lorlatinib exhibits substantial activity and tolerability when used clinically in a later-line setting in a Taiwanese population with ALK-positive advanced NSCLC.PMID:38195317 | DOI:10.1016/j.jfma.2023.12.019

Source: J Formos Med Assoc - January 9, 2024 Category: General Medicine Authors: Jin-Yuan Shih Yung-Hung Luo Gee-Chen Chang John Wen-Cheng Chang Chin-Chou Wang Tsung-Ying Yang Wei-Tse Fang Wen-Yi Shau Source Type: research